nodes	percent_of_prediction	percent_of_DWPC	metapath
Famotidine—CYP2C19—prostate cancer	0.261	1	CbGaD
Famotidine—SLC47A1—Mitoxantrone—prostate cancer	0.165	0.352	CbGbCtD
Famotidine—SLC22A2—Estradiol—prostate cancer	0.0492	0.105	CbGbCtD
Famotidine—SLC22A8—Conjugated Estrogens—prostate cancer	0.0481	0.103	CbGbCtD
Famotidine—CYP2C19—Nilutamide—prostate cancer	0.0472	0.101	CbGbCtD
Famotidine—CYP2C19—Bicalutamide—prostate cancer	0.0472	0.101	CbGbCtD
Famotidine—SLC22A8—Estradiol—prostate cancer	0.0422	0.0902	CbGbCtD
Famotidine—CYP2C19—Flutamide—prostate cancer	0.0391	0.0836	CbGbCtD
Famotidine—CYP2C19—Estradiol—prostate cancer	0.0162	0.0347	CbGbCtD
Famotidine—CYP2C19—Prednisone—prostate cancer	0.014	0.0298	CbGbCtD
Famotidine—SLC22A8—urine—prostate cancer	0.00362	0.206	CbGeAlD
Famotidine—CYP2C19—urine—prostate cancer	0.00304	0.172	CbGeAlD
Famotidine—SLC47A1—prostate gland—prostate cancer	0.00169	0.0962	CbGeAlD
Famotidine—SLC47A1—seminal vesicle—prostate cancer	0.00143	0.0814	CbGeAlD
Famotidine—SLC22A2—renal system—prostate cancer	0.00136	0.0775	CbGeAlD
Famotidine—SLC22A8—prostate gland—prostate cancer	0.0013	0.0738	CbGeAlD
Famotidine—SLC47A1—renal system—prostate cancer	0.00115	0.0656	CbGeAlD
Famotidine—SLC47A1—urethra—prostate cancer	0.00113	0.0644	CbGeAlD
Famotidine—SLC22A8—renal system—prostate cancer	0.000886	0.0503	CbGeAlD
Famotidine—SLC47A1—testis—prostate cancer	0.000746	0.0424	CbGeAlD
Famotidine—HRH2—lymph node—prostate cancer	0.000701	0.0398	CbGeAlD
Famotidine—SLC47A1—lymph node—prostate cancer	0.000541	0.0307	CbGeAlD
Famotidine—Dry mouth—Docetaxel—prostate cancer	6.78e-05	0.000355	CcSEcCtD
Famotidine—Upper respiratory tract infection—Doxorubicin—prostate cancer	6.78e-05	0.000355	CcSEcCtD
Famotidine—Pollakiuria—Doxorubicin—prostate cancer	6.74e-05	0.000353	CcSEcCtD
Famotidine—Myalgia—Capecitabine—prostate cancer	6.71e-05	0.000351	CcSEcCtD
Famotidine—Chest pain—Capecitabine—prostate cancer	6.71e-05	0.000351	CcSEcCtD
Famotidine—Arthralgia—Capecitabine—prostate cancer	6.71e-05	0.000351	CcSEcCtD
Famotidine—Haematuria—Epirubicin—prostate cancer	6.7e-05	0.000351	CcSEcCtD
Famotidine—Confusional state—Docetaxel—prostate cancer	6.7e-05	0.000351	CcSEcCtD
Famotidine—Anxiety—Capecitabine—prostate cancer	6.69e-05	0.00035	CcSEcCtD
Famotidine—Photosensitivity reaction—Doxorubicin—prostate cancer	6.66e-05	0.000349	CcSEcCtD
Famotidine—Oedema—Docetaxel—prostate cancer	6.65e-05	0.000348	CcSEcCtD
Famotidine—Anaphylactic shock—Docetaxel—prostate cancer	6.65e-05	0.000348	CcSEcCtD
Famotidine—Infection—Docetaxel—prostate cancer	6.6e-05	0.000346	CcSEcCtD
Famotidine—Sinusitis—Epirubicin—prostate cancer	6.6e-05	0.000345	CcSEcCtD
Famotidine—Feeling abnormal—Etoposide—prostate cancer	6.59e-05	0.000345	CcSEcCtD
Famotidine—Diarrhoea—Mitoxantrone—prostate cancer	6.58e-05	0.000344	CcSEcCtD
Famotidine—Dry mouth—Capecitabine—prostate cancer	6.57e-05	0.000344	CcSEcCtD
Famotidine—Vomiting—Estradiol—prostate cancer	6.56e-05	0.000343	CcSEcCtD
Famotidine—Agranulocytosis—Epirubicin—prostate cancer	6.56e-05	0.000343	CcSEcCtD
Famotidine—Gastrointestinal pain—Etoposide—prostate cancer	6.54e-05	0.000342	CcSEcCtD
Famotidine—Shock—Docetaxel—prostate cancer	6.54e-05	0.000342	CcSEcCtD
Famotidine—Thrombocytopenia—Docetaxel—prostate cancer	6.51e-05	0.000341	CcSEcCtD
Famotidine—Rash—Estradiol—prostate cancer	6.51e-05	0.000341	CcSEcCtD
Famotidine—Dermatitis—Estradiol—prostate cancer	6.5e-05	0.00034	CcSEcCtD
Famotidine—Anaemia—Prednisone—prostate cancer	6.49e-05	0.00034	CcSEcCtD
Famotidine—Confusional state—Capecitabine—prostate cancer	6.49e-05	0.00034	CcSEcCtD
Famotidine—Headache—Estradiol—prostate cancer	6.47e-05	0.000338	CcSEcCtD
Famotidine—Agitation—Prednisone—prostate cancer	6.45e-05	0.000338	CcSEcCtD
Famotidine—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	6.45e-05	0.000338	CcSEcCtD
Famotidine—Oedema—Capecitabine—prostate cancer	6.44e-05	0.000337	CcSEcCtD
Famotidine—Bradycardia—Epirubicin—prostate cancer	6.42e-05	0.000336	CcSEcCtD
Famotidine—Angioedema—Prednisone—prostate cancer	6.42e-05	0.000336	CcSEcCtD
Famotidine—Infection—Capecitabine—prostate cancer	6.39e-05	0.000335	CcSEcCtD
Famotidine—Urticaria—Etoposide—prostate cancer	6.35e-05	0.000333	CcSEcCtD
Famotidine—Jaundice—Doxorubicin—prostate cancer	6.34e-05	0.000332	CcSEcCtD
Famotidine—Anorexia—Docetaxel—prostate cancer	6.34e-05	0.000332	CcSEcCtD
Famotidine—Shock—Capecitabine—prostate cancer	6.33e-05	0.000331	CcSEcCtD
Famotidine—Abdominal pain—Etoposide—prostate cancer	6.32e-05	0.000331	CcSEcCtD
Famotidine—Body temperature increased—Etoposide—prostate cancer	6.32e-05	0.000331	CcSEcCtD
Famotidine—Hepatitis—Epirubicin—prostate cancer	6.31e-05	0.00033	CcSEcCtD
Famotidine—Thrombocytopenia—Capecitabine—prostate cancer	6.3e-05	0.00033	CcSEcCtD
Famotidine—Syncope—Prednisone—prostate cancer	6.3e-05	0.00033	CcSEcCtD
Famotidine—Pharyngitis—Epirubicin—prostate cancer	6.26e-05	0.000328	CcSEcCtD
Famotidine—Haematuria—Doxorubicin—prostate cancer	6.2e-05	0.000325	CcSEcCtD
Famotidine—Loss of consciousness—Prednisone—prostate cancer	6.17e-05	0.000323	CcSEcCtD
Famotidine—Anorexia—Capecitabine—prostate cancer	6.13e-05	0.000321	CcSEcCtD
Famotidine—Nausea—Estradiol—prostate cancer	6.13e-05	0.000321	CcSEcCtD
Famotidine—Vomiting—Mitoxantrone—prostate cancer	6.11e-05	0.00032	CcSEcCtD
Famotidine—Sinusitis—Doxorubicin—prostate cancer	6.1e-05	0.000319	CcSEcCtD
Famotidine—Convulsion—Prednisone—prostate cancer	6.09e-05	0.000319	CcSEcCtD
Famotidine—Agranulocytosis—Doxorubicin—prostate cancer	6.07e-05	0.000318	CcSEcCtD
Famotidine—Rash—Mitoxantrone—prostate cancer	6.06e-05	0.000317	CcSEcCtD
Famotidine—Dermatitis—Mitoxantrone—prostate cancer	6.06e-05	0.000317	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.06e-05	0.000317	CcSEcCtD
Famotidine—Headache—Mitoxantrone—prostate cancer	6.02e-05	0.000315	CcSEcCtD
Famotidine—Insomnia—Docetaxel—prostate cancer	6.01e-05	0.000315	CcSEcCtD
Famotidine—Arthralgia—Prednisone—prostate cancer	5.98e-05	0.000313	CcSEcCtD
Famotidine—Myalgia—Prednisone—prostate cancer	5.98e-05	0.000313	CcSEcCtD
Famotidine—Paraesthesia—Docetaxel—prostate cancer	5.97e-05	0.000312	CcSEcCtD
Famotidine—Erythema multiforme—Epirubicin—prostate cancer	5.97e-05	0.000312	CcSEcCtD
Famotidine—Anxiety—Prednisone—prostate cancer	5.96e-05	0.000312	CcSEcCtD
Famotidine—Bradycardia—Doxorubicin—prostate cancer	5.94e-05	0.000311	CcSEcCtD
Famotidine—Somnolence—Docetaxel—prostate cancer	5.91e-05	0.000309	CcSEcCtD
Famotidine—Hypersensitivity—Etoposide—prostate cancer	5.89e-05	0.000308	CcSEcCtD
Famotidine—Tinnitus—Epirubicin—prostate cancer	5.88e-05	0.000308	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.86e-05	0.000307	CcSEcCtD
Famotidine—Flushing—Epirubicin—prostate cancer	5.86e-05	0.000307	CcSEcCtD
Famotidine—Dyspepsia—Docetaxel—prostate cancer	5.85e-05	0.000306	CcSEcCtD
Famotidine—Hepatitis—Doxorubicin—prostate cancer	5.84e-05	0.000306	CcSEcCtD
Famotidine—Insomnia—Capecitabine—prostate cancer	5.82e-05	0.000305	CcSEcCtD
Famotidine—Pharyngitis—Doxorubicin—prostate cancer	5.8e-05	0.000303	CcSEcCtD
Famotidine—Paraesthesia—Capecitabine—prostate cancer	5.78e-05	0.000302	CcSEcCtD
Famotidine—Decreased appetite—Docetaxel—prostate cancer	5.78e-05	0.000302	CcSEcCtD
Famotidine—Asthenia—Etoposide—prostate cancer	5.74e-05	0.0003	CcSEcCtD
Famotidine—Anaphylactic shock—Prednisone—prostate cancer	5.73e-05	0.0003	CcSEcCtD
Famotidine—Oedema—Prednisone—prostate cancer	5.73e-05	0.0003	CcSEcCtD
Famotidine—Fatigue—Docetaxel—prostate cancer	5.73e-05	0.0003	CcSEcCtD
Famotidine—Nausea—Mitoxantrone—prostate cancer	5.71e-05	0.000299	CcSEcCtD
Famotidine—Infection—Prednisone—prostate cancer	5.7e-05	0.000298	CcSEcCtD
Famotidine—Pain—Docetaxel—prostate cancer	5.68e-05	0.000298	CcSEcCtD
Famotidine—Constipation—Docetaxel—prostate cancer	5.68e-05	0.000298	CcSEcCtD
Famotidine—Dyspepsia—Capecitabine—prostate cancer	5.67e-05	0.000297	CcSEcCtD
Famotidine—Pruritus—Etoposide—prostate cancer	5.66e-05	0.000296	CcSEcCtD
Famotidine—Shock—Prednisone—prostate cancer	5.64e-05	0.000295	CcSEcCtD
Famotidine—Arrhythmia—Epirubicin—prostate cancer	5.64e-05	0.000295	CcSEcCtD
Famotidine—Decreased appetite—Capecitabine—prostate cancer	5.59e-05	0.000293	CcSEcCtD
Famotidine—Alopecia—Epirubicin—prostate cancer	5.58e-05	0.000292	CcSEcCtD
Famotidine—Fatigue—Capecitabine—prostate cancer	5.55e-05	0.00029	CcSEcCtD
Famotidine—Mental disorder—Epirubicin—prostate cancer	5.53e-05	0.000289	CcSEcCtD
Famotidine—Erythema multiforme—Doxorubicin—prostate cancer	5.52e-05	0.000289	CcSEcCtD
Famotidine—Pain—Capecitabine—prostate cancer	5.5e-05	0.000288	CcSEcCtD
Famotidine—Constipation—Capecitabine—prostate cancer	5.5e-05	0.000288	CcSEcCtD
Famotidine—Feeling abnormal—Docetaxel—prostate cancer	5.48e-05	0.000287	CcSEcCtD
Famotidine—Diarrhoea—Etoposide—prostate cancer	5.47e-05	0.000286	CcSEcCtD
Famotidine—Anorexia—Prednisone—prostate cancer	5.46e-05	0.000286	CcSEcCtD
Famotidine—Tinnitus—Doxorubicin—prostate cancer	5.44e-05	0.000285	CcSEcCtD
Famotidine—Gastrointestinal pain—Docetaxel—prostate cancer	5.44e-05	0.000284	CcSEcCtD
Famotidine—Flushing—Doxorubicin—prostate cancer	5.42e-05	0.000284	CcSEcCtD
Famotidine—Dysgeusia—Epirubicin—prostate cancer	5.38e-05	0.000282	CcSEcCtD
Famotidine—Back pain—Epirubicin—prostate cancer	5.31e-05	0.000278	CcSEcCtD
Famotidine—Feeling abnormal—Capecitabine—prostate cancer	5.3e-05	0.000278	CcSEcCtD
Famotidine—Dizziness—Etoposide—prostate cancer	5.29e-05	0.000277	CcSEcCtD
Famotidine—Muscle spasms—Epirubicin—prostate cancer	5.28e-05	0.000276	CcSEcCtD
Famotidine—Gastrointestinal pain—Capecitabine—prostate cancer	5.26e-05	0.000275	CcSEcCtD
Famotidine—Abdominal pain—Docetaxel—prostate cancer	5.25e-05	0.000275	CcSEcCtD
Famotidine—Body temperature increased—Docetaxel—prostate cancer	5.25e-05	0.000275	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Prednisone—prostate cancer	5.22e-05	0.000273	CcSEcCtD
Famotidine—Arrhythmia—Doxorubicin—prostate cancer	5.22e-05	0.000273	CcSEcCtD
Famotidine—Insomnia—Prednisone—prostate cancer	5.18e-05	0.000271	CcSEcCtD
Famotidine—Alopecia—Doxorubicin—prostate cancer	5.16e-05	0.00027	CcSEcCtD
Famotidine—Paraesthesia—Prednisone—prostate cancer	5.15e-05	0.000269	CcSEcCtD
Famotidine—Mental disorder—Doxorubicin—prostate cancer	5.12e-05	0.000268	CcSEcCtD
Famotidine—Urticaria—Capecitabine—prostate cancer	5.11e-05	0.000268	CcSEcCtD
Famotidine—Abdominal pain—Capecitabine—prostate cancer	5.09e-05	0.000266	CcSEcCtD
Famotidine—Body temperature increased—Capecitabine—prostate cancer	5.09e-05	0.000266	CcSEcCtD
Famotidine—Vomiting—Etoposide—prostate cancer	5.09e-05	0.000266	CcSEcCtD
Famotidine—Anaemia—Epirubicin—prostate cancer	5.08e-05	0.000266	CcSEcCtD
Famotidine—Agitation—Epirubicin—prostate cancer	5.05e-05	0.000264	CcSEcCtD
Famotidine—Dyspepsia—Prednisone—prostate cancer	5.05e-05	0.000264	CcSEcCtD
Famotidine—Rash—Etoposide—prostate cancer	5.04e-05	0.000264	CcSEcCtD
Famotidine—Dermatitis—Etoposide—prostate cancer	5.04e-05	0.000264	CcSEcCtD
Famotidine—Headache—Etoposide—prostate cancer	5.01e-05	0.000262	CcSEcCtD
Famotidine—Decreased appetite—Prednisone—prostate cancer	4.98e-05	0.000261	CcSEcCtD
Famotidine—Dysgeusia—Doxorubicin—prostate cancer	4.98e-05	0.000261	CcSEcCtD
Famotidine—Fatigue—Prednisone—prostate cancer	4.94e-05	0.000259	CcSEcCtD
Famotidine—Syncope—Epirubicin—prostate cancer	4.93e-05	0.000258	CcSEcCtD
Famotidine—Leukopenia—Epirubicin—prostate cancer	4.92e-05	0.000257	CcSEcCtD
Famotidine—Back pain—Doxorubicin—prostate cancer	4.92e-05	0.000257	CcSEcCtD
Famotidine—Constipation—Prednisone—prostate cancer	4.9e-05	0.000257	CcSEcCtD
Famotidine—Hypersensitivity—Docetaxel—prostate cancer	4.9e-05	0.000256	CcSEcCtD
Famotidine—Muscle spasms—Doxorubicin—prostate cancer	4.89e-05	0.000256	CcSEcCtD
Famotidine—Palpitations—Epirubicin—prostate cancer	4.85e-05	0.000254	CcSEcCtD
Famotidine—Loss of consciousness—Epirubicin—prostate cancer	4.83e-05	0.000253	CcSEcCtD
Famotidine—Cough—Epirubicin—prostate cancer	4.79e-05	0.000251	CcSEcCtD
Famotidine—Asthenia—Docetaxel—prostate cancer	4.77e-05	0.00025	CcSEcCtD
Famotidine—Convulsion—Epirubicin—prostate cancer	4.76e-05	0.000249	CcSEcCtD
Famotidine—Nausea—Etoposide—prostate cancer	4.75e-05	0.000249	CcSEcCtD
Famotidine—Hypersensitivity—Capecitabine—prostate cancer	4.74e-05	0.000248	CcSEcCtD
Famotidine—Feeling abnormal—Prednisone—prostate cancer	4.72e-05	0.000247	CcSEcCtD
Famotidine—Pruritus—Docetaxel—prostate cancer	4.7e-05	0.000246	CcSEcCtD
Famotidine—Anaemia—Doxorubicin—prostate cancer	4.7e-05	0.000246	CcSEcCtD
Famotidine—Gastrointestinal pain—Prednisone—prostate cancer	4.69e-05	0.000245	CcSEcCtD
Famotidine—Myalgia—Epirubicin—prostate cancer	4.68e-05	0.000245	CcSEcCtD
Famotidine—Chest pain—Epirubicin—prostate cancer	4.68e-05	0.000245	CcSEcCtD
Famotidine—Arthralgia—Epirubicin—prostate cancer	4.68e-05	0.000245	CcSEcCtD
Famotidine—Agitation—Doxorubicin—prostate cancer	4.67e-05	0.000244	CcSEcCtD
Famotidine—Anxiety—Epirubicin—prostate cancer	4.66e-05	0.000244	CcSEcCtD
Famotidine—Asthenia—Capecitabine—prostate cancer	4.62e-05	0.000242	CcSEcCtD
Famotidine—Dry mouth—Epirubicin—prostate cancer	4.57e-05	0.000239	CcSEcCtD
Famotidine—Syncope—Doxorubicin—prostate cancer	4.56e-05	0.000239	CcSEcCtD
Famotidine—Urticaria—Prednisone—prostate cancer	4.55e-05	0.000238	CcSEcCtD
Famotidine—Pruritus—Capecitabine—prostate cancer	4.55e-05	0.000238	CcSEcCtD
Famotidine—Leukopenia—Doxorubicin—prostate cancer	4.55e-05	0.000238	CcSEcCtD
Famotidine—Diarrhoea—Docetaxel—prostate cancer	4.55e-05	0.000238	CcSEcCtD
Famotidine—Body temperature increased—Prednisone—prostate cancer	4.53e-05	0.000237	CcSEcCtD
Famotidine—Abdominal pain—Prednisone—prostate cancer	4.53e-05	0.000237	CcSEcCtD
Famotidine—Confusional state—Epirubicin—prostate cancer	4.52e-05	0.000237	CcSEcCtD
Famotidine—Palpitations—Doxorubicin—prostate cancer	4.49e-05	0.000235	CcSEcCtD
Famotidine—Oedema—Epirubicin—prostate cancer	4.48e-05	0.000235	CcSEcCtD
Famotidine—Anaphylactic shock—Epirubicin—prostate cancer	4.48e-05	0.000235	CcSEcCtD
Famotidine—Loss of consciousness—Doxorubicin—prostate cancer	4.47e-05	0.000234	CcSEcCtD
Famotidine—Infection—Epirubicin—prostate cancer	4.45e-05	0.000233	CcSEcCtD
Famotidine—Cough—Doxorubicin—prostate cancer	4.44e-05	0.000232	CcSEcCtD
Famotidine—Shock—Epirubicin—prostate cancer	4.41e-05	0.000231	CcSEcCtD
Famotidine—Convulsion—Doxorubicin—prostate cancer	4.4e-05	0.000231	CcSEcCtD
Famotidine—Diarrhoea—Capecitabine—prostate cancer	4.4e-05	0.00023	CcSEcCtD
Famotidine—Dizziness—Docetaxel—prostate cancer	4.4e-05	0.00023	CcSEcCtD
Famotidine—Thrombocytopenia—Epirubicin—prostate cancer	4.39e-05	0.00023	CcSEcCtD
Famotidine—Chest pain—Doxorubicin—prostate cancer	4.33e-05	0.000227	CcSEcCtD
Famotidine—Arthralgia—Doxorubicin—prostate cancer	4.33e-05	0.000227	CcSEcCtD
Famotidine—Myalgia—Doxorubicin—prostate cancer	4.33e-05	0.000227	CcSEcCtD
Famotidine—Anxiety—Doxorubicin—prostate cancer	4.31e-05	0.000226	CcSEcCtD
Famotidine—Anorexia—Epirubicin—prostate cancer	4.27e-05	0.000224	CcSEcCtD
Famotidine—Dizziness—Capecitabine—prostate cancer	4.26e-05	0.000223	CcSEcCtD
Famotidine—Dry mouth—Doxorubicin—prostate cancer	4.23e-05	0.000222	CcSEcCtD
Famotidine—Vomiting—Docetaxel—prostate cancer	4.23e-05	0.000221	CcSEcCtD
Famotidine—Hypersensitivity—Prednisone—prostate cancer	4.22e-05	0.000221	CcSEcCtD
Famotidine—Rash—Docetaxel—prostate cancer	4.19e-05	0.000219	CcSEcCtD
Famotidine—Dermatitis—Docetaxel—prostate cancer	4.19e-05	0.000219	CcSEcCtD
Famotidine—Confusional state—Doxorubicin—prostate cancer	4.18e-05	0.000219	CcSEcCtD
Famotidine—Headache—Docetaxel—prostate cancer	4.16e-05	0.000218	CcSEcCtD
Famotidine—Anaphylactic shock—Doxorubicin—prostate cancer	4.15e-05	0.000217	CcSEcCtD
Famotidine—Oedema—Doxorubicin—prostate cancer	4.15e-05	0.000217	CcSEcCtD
Famotidine—Infection—Doxorubicin—prostate cancer	4.12e-05	0.000216	CcSEcCtD
Famotidine—Asthenia—Prednisone—prostate cancer	4.11e-05	0.000215	CcSEcCtD
Famotidine—Vomiting—Capecitabine—prostate cancer	4.09e-05	0.000214	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.08e-05	0.000214	CcSEcCtD
Famotidine—Shock—Doxorubicin—prostate cancer	4.08e-05	0.000214	CcSEcCtD
Famotidine—Thrombocytopenia—Doxorubicin—prostate cancer	4.06e-05	0.000213	CcSEcCtD
Famotidine—Rash—Capecitabine—prostate cancer	4.06e-05	0.000212	CcSEcCtD
Famotidine—Pruritus—Prednisone—prostate cancer	4.06e-05	0.000212	CcSEcCtD
Famotidine—Insomnia—Epirubicin—prostate cancer	4.06e-05	0.000212	CcSEcCtD
Famotidine—Dermatitis—Capecitabine—prostate cancer	4.05e-05	0.000212	CcSEcCtD
Famotidine—Headache—Capecitabine—prostate cancer	4.03e-05	0.000211	CcSEcCtD
Famotidine—Paraesthesia—Epirubicin—prostate cancer	4.03e-05	0.000211	CcSEcCtD
Famotidine—Somnolence—Epirubicin—prostate cancer	3.99e-05	0.000209	CcSEcCtD
Famotidine—Anorexia—Doxorubicin—prostate cancer	3.95e-05	0.000207	CcSEcCtD
Famotidine—Nausea—Docetaxel—prostate cancer	3.95e-05	0.000207	CcSEcCtD
Famotidine—Dyspepsia—Epirubicin—prostate cancer	3.95e-05	0.000207	CcSEcCtD
Famotidine—Diarrhoea—Prednisone—prostate cancer	3.92e-05	0.000205	CcSEcCtD
Famotidine—Decreased appetite—Epirubicin—prostate cancer	3.9e-05	0.000204	CcSEcCtD
Famotidine—Fatigue—Epirubicin—prostate cancer	3.87e-05	0.000202	CcSEcCtD
Famotidine—Pain—Epirubicin—prostate cancer	3.83e-05	0.000201	CcSEcCtD
Famotidine—Constipation—Epirubicin—prostate cancer	3.83e-05	0.000201	CcSEcCtD
Famotidine—Nausea—Capecitabine—prostate cancer	3.82e-05	0.0002	CcSEcCtD
Famotidine—Dizziness—Prednisone—prostate cancer	3.79e-05	0.000198	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.78e-05	0.000198	CcSEcCtD
Famotidine—Insomnia—Doxorubicin—prostate cancer	3.75e-05	0.000196	CcSEcCtD
Famotidine—Paraesthesia—Doxorubicin—prostate cancer	3.73e-05	0.000195	CcSEcCtD
Famotidine—Feeling abnormal—Epirubicin—prostate cancer	3.69e-05	0.000193	CcSEcCtD
Famotidine—Somnolence—Doxorubicin—prostate cancer	3.69e-05	0.000193	CcSEcCtD
Famotidine—Gastrointestinal pain—Epirubicin—prostate cancer	3.67e-05	0.000192	CcSEcCtD
Famotidine—Dyspepsia—Doxorubicin—prostate cancer	3.65e-05	0.000191	CcSEcCtD
Famotidine—Vomiting—Prednisone—prostate cancer	3.64e-05	0.000191	CcSEcCtD
Famotidine—Rash—Prednisone—prostate cancer	3.61e-05	0.000189	CcSEcCtD
Famotidine—Dermatitis—Prednisone—prostate cancer	3.61e-05	0.000189	CcSEcCtD
Famotidine—Decreased appetite—Doxorubicin—prostate cancer	3.61e-05	0.000189	CcSEcCtD
Famotidine—Headache—Prednisone—prostate cancer	3.59e-05	0.000188	CcSEcCtD
Famotidine—Fatigue—Doxorubicin—prostate cancer	3.58e-05	0.000187	CcSEcCtD
Famotidine—Urticaria—Epirubicin—prostate cancer	3.56e-05	0.000186	CcSEcCtD
Famotidine—Pain—Doxorubicin—prostate cancer	3.55e-05	0.000186	CcSEcCtD
Famotidine—Constipation—Doxorubicin—prostate cancer	3.55e-05	0.000186	CcSEcCtD
Famotidine—Body temperature increased—Epirubicin—prostate cancer	3.54e-05	0.000186	CcSEcCtD
Famotidine—Abdominal pain—Epirubicin—prostate cancer	3.54e-05	0.000186	CcSEcCtD
Famotidine—Feeling abnormal—Doxorubicin—prostate cancer	3.42e-05	0.000179	CcSEcCtD
Famotidine—Nausea—Prednisone—prostate cancer	3.41e-05	0.000178	CcSEcCtD
Famotidine—Gastrointestinal pain—Doxorubicin—prostate cancer	3.39e-05	0.000178	CcSEcCtD
Famotidine—Hypersensitivity—Epirubicin—prostate cancer	3.3e-05	0.000173	CcSEcCtD
Famotidine—Urticaria—Doxorubicin—prostate cancer	3.3e-05	0.000172	CcSEcCtD
Famotidine—Abdominal pain—Doxorubicin—prostate cancer	3.28e-05	0.000172	CcSEcCtD
Famotidine—Body temperature increased—Doxorubicin—prostate cancer	3.28e-05	0.000172	CcSEcCtD
Famotidine—Asthenia—Epirubicin—prostate cancer	3.22e-05	0.000168	CcSEcCtD
Famotidine—Pruritus—Epirubicin—prostate cancer	3.17e-05	0.000166	CcSEcCtD
Famotidine—Diarrhoea—Epirubicin—prostate cancer	3.07e-05	0.000161	CcSEcCtD
Famotidine—Hypersensitivity—Doxorubicin—prostate cancer	3.06e-05	0.00016	CcSEcCtD
Famotidine—Asthenia—Doxorubicin—prostate cancer	2.98e-05	0.000156	CcSEcCtD
Famotidine—Dizziness—Epirubicin—prostate cancer	2.96e-05	0.000155	CcSEcCtD
Famotidine—Pruritus—Doxorubicin—prostate cancer	2.94e-05	0.000154	CcSEcCtD
Famotidine—Vomiting—Epirubicin—prostate cancer	2.85e-05	0.000149	CcSEcCtD
Famotidine—Diarrhoea—Doxorubicin—prostate cancer	2.84e-05	0.000149	CcSEcCtD
Famotidine—Rash—Epirubicin—prostate cancer	2.83e-05	0.000148	CcSEcCtD
Famotidine—Dermatitis—Epirubicin—prostate cancer	2.82e-05	0.000148	CcSEcCtD
Famotidine—Headache—Epirubicin—prostate cancer	2.81e-05	0.000147	CcSEcCtD
Famotidine—Dizziness—Doxorubicin—prostate cancer	2.74e-05	0.000144	CcSEcCtD
Famotidine—Nausea—Epirubicin—prostate cancer	2.66e-05	0.000139	CcSEcCtD
Famotidine—Vomiting—Doxorubicin—prostate cancer	2.64e-05	0.000138	CcSEcCtD
Famotidine—Rash—Doxorubicin—prostate cancer	2.62e-05	0.000137	CcSEcCtD
Famotidine—Dermatitis—Doxorubicin—prostate cancer	2.61e-05	0.000137	CcSEcCtD
Famotidine—Headache—Doxorubicin—prostate cancer	2.6e-05	0.000136	CcSEcCtD
Famotidine—Nausea—Doxorubicin—prostate cancer	2.46e-05	0.000129	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—PRKCZ—prostate cancer	1.82e-05	0.000291	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SULT1A1—prostate cancer	1.82e-05	0.000291	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ABCG5—prostate cancer	1.82e-05	0.000291	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AMACR—prostate cancer	1.79e-05	0.000287	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP3A43—prostate cancer	1.79e-05	0.000287	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SRD5A2—prostate cancer	1.79e-05	0.000287	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—DEGS1—prostate cancer	1.79e-05	0.000287	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NAT1—prostate cancer	1.79e-05	0.000287	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CG—prostate cancer	1.78e-05	0.000284	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTA1—prostate cancer	1.78e-05	0.000284	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	1.76e-05	0.000282	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PARP1—prostate cancer	1.76e-05	0.000281	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FGFR4—prostate cancer	1.76e-05	0.000281	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTO1—prostate cancer	1.76e-05	0.000281	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—HSD3B2—prostate cancer	1.76e-05	0.000281	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NAT2—prostate cancer	1.76e-05	0.000281	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CALCA—prostate cancer	1.74e-05	0.000278	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HSD17B1—prostate cancer	1.71e-05	0.000274	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	1.71e-05	0.000274	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CXCL12—prostate cancer	1.69e-05	0.000271	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PLCB2—prostate cancer	1.68e-05	0.000269	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—LRP2—prostate cancer	1.68e-05	0.000269	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP2C18—prostate cancer	1.68e-05	0.000269	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—P4HB—prostate cancer	1.65e-05	0.000264	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	1.65e-05	0.000263	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	1.64e-05	0.000262	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	1.62e-05	0.000259	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CG—prostate cancer	1.61e-05	0.000258	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SLC22A1—prostate cancer	1.61e-05	0.000257	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—PPARA—prostate cancer	1.61e-05	0.000257	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CASP9—prostate cancer	1.6e-05	0.000255	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SULT2A1—prostate cancer	1.57e-05	0.00025	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CD—prostate cancer	1.56e-05	0.00025	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PRKCQ—prostate cancer	1.55e-05	0.000247	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NGFR—prostate cancer	1.55e-05	0.000247	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	1.54e-05	0.000247	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—MED12—prostate cancer	1.54e-05	0.000246	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MAP3K7—prostate cancer	1.53e-05	0.000244	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GNG5—prostate cancer	1.53e-05	0.000244	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—B4GALT4—prostate cancer	1.53e-05	0.000244	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HPGD—prostate cancer	1.53e-05	0.000244	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NCOA3—prostate cancer	1.47e-05	0.000235	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FGF10—prostate cancer	1.47e-05	0.000235	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ADRB2—prostate cancer	1.45e-05	0.000233	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TNFRSF21—prostate cancer	1.43e-05	0.000229	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—JAK2—prostate cancer	1.43e-05	0.000229	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—MAP2K1—prostate cancer	1.43e-05	0.000228	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CD—prostate cancer	1.42e-05	0.000227	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—VAV3—prostate cancer	1.42e-05	0.000227	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—HPGDS—prostate cancer	1.4e-05	0.000225	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TGFBR2—prostate cancer	1.4e-05	0.000224	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP7B1—prostate cancer	1.4e-05	0.000223	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—MTAP—prostate cancer	1.4e-05	0.000223	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP2C19—prostate cancer	1.4e-05	0.000223	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ITPR1—prostate cancer	1.38e-05	0.00022	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	1.36e-05	0.000218	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CB—prostate cancer	1.36e-05	0.000218	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ACHE—prostate cancer	1.36e-05	0.000218	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTT1—prostate cancer	1.36e-05	0.000218	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SULT1E1—prostate cancer	1.36e-05	0.000217	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SRD5A1—prostate cancer	1.36e-05	0.000217	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP2A6—prostate cancer	1.35e-05	0.000215	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	1.32e-05	0.000211	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IGF1R—prostate cancer	1.31e-05	0.00021	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—AKR1C3—prostate cancer	1.31e-05	0.000209	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CXCL8—prostate cancer	1.31e-05	0.000209	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PRKACB—prostate cancer	1.3e-05	0.000208	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—JAK2—prostate cancer	1.3e-05	0.000208	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	1.3e-05	0.000208	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HSD17B3—prostate cancer	1.3e-05	0.000207	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ACSL4—prostate cancer	1.3e-05	0.000207	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP17A1—prostate cancer	1.29e-05	0.000206	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	1.28e-05	0.000205	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.28e-05	0.000204	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—LPL—prostate cancer	1.26e-05	0.000202	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—IL2—prostate cancer	1.25e-05	0.0002	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PDGFRB—prostate cancer	1.25e-05	0.0002	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ARG2—prostate cancer	1.24e-05	0.000199	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—UMPS—prostate cancer	1.24e-05	0.000199	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PHGDH—prostate cancer	1.24e-05	0.000199	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	1.24e-05	0.000198	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CB—prostate cancer	1.24e-05	0.000198	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NCOA2—prostate cancer	1.23e-05	0.000196	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—LDHB—prostate cancer	1.22e-05	0.000195	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ITGB3—prostate cancer	1.22e-05	0.000195	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP3A5—prostate cancer	1.2e-05	0.000191	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CXCL8—prostate cancer	1.19e-05	0.00019	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ERBB3—prostate cancer	1.18e-05	0.000189	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FGFR2—prostate cancer	1.18e-05	0.000189	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SLC5A5—prostate cancer	1.17e-05	0.000187	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TCN2—prostate cancer	1.16e-05	0.000185	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PDHA1—prostate cancer	1.16e-05	0.000185	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTA3—prostate cancer	1.16e-05	0.000185	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—UCP3—prostate cancer	1.16e-05	0.000185	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP2E1—prostate cancer	1.14e-05	0.000183	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—IL2—prostate cancer	1.14e-05	0.000182	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TERT—prostate cancer	1.13e-05	0.000181	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NQO1—prostate cancer	1.13e-05	0.000181	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—TH—prostate cancer	1.12e-05	0.000178	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP3A4—prostate cancer	1.1e-05	0.000177	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HSD3B1—prostate cancer	1.1e-05	0.000176	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SLC22A3—prostate cancer	1.1e-05	0.000176	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP1B1—prostate cancer	1.09e-05	0.000174	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HIF1A—prostate cancer	1.08e-05	0.000173	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.07e-05	0.000171	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTA4—prostate cancer	1.06e-05	0.000169	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TBXAS1—prostate cancer	1.06e-05	0.000169	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—LEP—prostate cancer	1.06e-05	0.000169	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GGT1—prostate cancer	1.05e-05	0.000168	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CAV1—prostate cancer	1.05e-05	0.000167	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—KDR—prostate cancer	1.04e-05	0.000166	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NCOA1—prostate cancer	1.04e-05	0.000166	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.03e-05	0.000165	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTA2—prostate cancer	1.03e-05	0.000165	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP19A1—prostate cancer	1.02e-05	0.000163	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ABCG5—prostate cancer	1.02e-05	0.000163	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SULT1A1—prostate cancer	1.02e-05	0.000163	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ESR1—prostate cancer	1.01e-05	0.000161	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTA1—prostate cancer	9.94e-06	0.000159	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—BAD—prostate cancer	9.85e-06	0.000157	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—RXRA—prostate cancer	9.85e-06	0.000157	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NAT2—prostate cancer	9.83e-06	0.000157	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTO1—prostate cancer	9.83e-06	0.000157	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HSD3B2—prostate cancer	9.83e-06	0.000157	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—APC—prostate cancer	9.54e-06	0.000153	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CG—prostate cancer	9.54e-06	0.000153	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—COMT—prostate cancer	9.49e-06	0.000152	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	9.45e-06	0.000151	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTP1—prostate cancer	9.44e-06	0.000151	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—EGF—prostate cancer	9.43e-06	0.000151	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IRS1—prostate cancer	9.43e-06	0.000151	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP2C18—prostate cancer	9.43e-06	0.000151	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—LRP2—prostate cancer	9.43e-06	0.000151	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PLCB2—prostate cancer	9.43e-06	0.000151	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ITPR1—prostate cancer	9.29e-06	0.000149	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—P4HB—prostate cancer	9.24e-06	0.000148	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GSK3B—prostate cancer	9.15e-06	0.000146	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—INS—prostate cancer	9.03e-06	0.000144	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SLC22A1—prostate cancer	8.99e-06	0.000144	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	8.89e-06	0.000142	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CREBBP—prostate cancer	8.84e-06	0.000141	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—TYMS—prostate cancer	8.78e-06	0.00014	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SULT2A1—prostate cancer	8.76e-06	0.00014	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IGF1—prostate cancer	8.73e-06	0.00014	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—EGFR—prostate cancer	8.69e-06	0.000139	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GSTM1—prostate cancer	8.68e-06	0.000139	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—MED12—prostate cancer	8.62e-06	0.000138	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GNG5—prostate cancer	8.55e-06	0.000137	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—LPL—prostate cancer	8.52e-06	0.000136	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MAP2K1—prostate cancer	8.44e-06	0.000135	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CD—prostate cancer	8.38e-06	0.000134	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CA—prostate cancer	8.3e-06	0.000133	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SERPINE1—prostate cancer	8.29e-06	0.000133	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NCOA3—prostate cancer	8.24e-06	0.000132	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP1A1—prostate cancer	8.22e-06	0.000132	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—KRAS—prostate cancer	8.21e-06	0.000131	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ERCC2—prostate cancer	8.16e-06	0.00013	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	8.1e-06	0.000129	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—FGF2—prostate cancer	8.03e-06	0.000128	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NOS3—prostate cancer	7.92e-06	0.000127	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—HPGDS—prostate cancer	7.86e-06	0.000126	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—JAK2—prostate cancer	7.69e-06	0.000123	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—MTHFR—prostate cancer	7.67e-06	0.000123	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ACHE—prostate cancer	7.62e-06	0.000122	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTT1—prostate cancer	7.62e-06	0.000122	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CA—prostate cancer	7.54e-06	0.000121	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP2A6—prostate cancer	7.54e-06	0.000121	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PPARA—prostate cancer	7.52e-06	0.00012	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MDM2—prostate cancer	7.51e-06	0.00012	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	7.51e-06	0.00012	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ERBB2—prostate cancer	7.41e-06	0.000118	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AKR1C3—prostate cancer	7.33e-06	0.000117	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CB—prostate cancer	7.31e-06	0.000117	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PRKACB—prostate cancer	7.29e-06	0.000117	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP17A1—prostate cancer	7.22e-06	0.000115	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	7.12e-06	0.000114	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CAV1—prostate cancer	7.07e-06	0.000113	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CXCL8—prostate cancer	7.02e-06	0.000112	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NCOA2—prostate cancer	6.88e-06	0.00011	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CDKN1B—prostate cancer	6.86e-06	0.00011	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—AKT1—prostate cancer	6.78e-06	0.000108	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CASP3—prostate cancer	6.72e-06	0.000107	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL2—prostate cancer	6.71e-06	0.000107	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—IL6—prostate cancer	6.68e-06	0.000107	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SLC5A5—prostate cancer	6.56e-06	0.000105	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCND1—prostate cancer	6.54e-06	0.000105	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CTNNB1—prostate cancer	6.48e-06	0.000104	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CG—prostate cancer	6.44e-06	0.000103	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP2E1—prostate cancer	6.41e-06	0.000102	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MMP9—prostate cancer	6.35e-06	0.000102	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NQO1—prostate cancer	6.34e-06	0.000101	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CDKN1A—prostate cancer	6.33e-06	0.000101	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTEN—prostate cancer	6.31e-06	0.000101	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TH—prostate cancer	6.24e-06	9.99e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	6.2e-06	9.92e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP3A4—prostate cancer	6.18e-06	9.88e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—AKT1—prostate cancer	6.16e-06	9.85e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	6.15e-06	9.83e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—INS—prostate cancer	6.1e-06	9.75e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP1B1—prostate cancer	6.07e-06	9.71e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—EP300—prostate cancer	6.02e-06	9.63e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CREBBP—prostate cancer	5.97e-06	9.55e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GGT1—prostate cancer	5.88e-06	9.41e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SRC—prostate cancer	5.86e-06	9.37e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NCOA1—prostate cancer	5.79e-06	9.27e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP19A1—prostate cancer	5.71e-06	9.13e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—VEGFA—prostate cancer	5.7e-06	9.12e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CD—prostate cancer	5.66e-06	9.06e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—STAT3—prostate cancer	5.65e-06	9.03e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—RXRA—prostate cancer	5.51e-06	8.81e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.36e-06	8.57e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—NOS3—prostate cancer	5.35e-06	8.55e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—COMT—prostate cancer	5.31e-06	8.49e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTP1—prostate cancer	5.28e-06	8.45e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MYC—prostate cancer	5.25e-06	8.39e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TGFB1—prostate cancer	5.23e-06	8.37e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ITPR1—prostate cancer	5.2e-06	8.32e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—EGFR—prostate cancer	5.13e-06	8.21e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.11e-06	8.18e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CB—prostate cancer	4.94e-06	7.89e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TYMS—prostate cancer	4.91e-06	7.86e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PTGS2—prostate cancer	4.89e-06	7.82e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GSTM1—prostate cancer	4.86e-06	7.77e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—KRAS—prostate cancer	4.85e-06	7.75e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—LPL—prostate cancer	4.77e-06	7.62e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP1A1—prostate cancer	4.6e-06	7.36e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ERCC2—prostate cancer	4.57e-06	7.3e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CA—prostate cancer	4.45e-06	7.12e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TP53—prostate cancer	4.31e-06	6.89e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—MTHFR—prostate cancer	4.29e-06	6.86e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PTEN—prostate cancer	4.27e-06	6.82e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PPARA—prostate cancer	4.21e-06	6.73e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—EP300—prostate cancer	4.07e-06	6.51e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CAV1—prostate cancer	3.96e-06	6.33e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL6—prostate cancer	3.94e-06	6.31e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.78e-06	6.05e-05	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—AKT1—prostate cancer	3.64e-06	5.82e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CG—prostate cancer	3.61e-06	5.77e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—INS—prostate cancer	3.41e-06	5.46e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CREBBP—prostate cancer	3.34e-06	5.35e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CD—prostate cancer	3.17e-06	5.07e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CA—prostate cancer	3.01e-06	4.81e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—NOS3—prostate cancer	2.99e-06	4.79e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CB—prostate cancer	2.76e-06	4.42e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PTGS2—prostate cancer	2.74e-06	4.38e-05	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—AKT1—prostate cancer	2.46e-06	3.93e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PTEN—prostate cancer	2.39e-06	3.82e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—EP300—prostate cancer	2.28e-06	3.64e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.68e-06	2.69e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AKT1—prostate cancer	1.38e-06	2.2e-05	CbGpPWpGaD
